1 Martinez-Elbal L, Ruiz-Nodar JM, Zueco J, et al. Drect coronary stenting versus stenting with balloon pre-dilation:immediate and follow-up results of a multicentre, prospective randomized study.The DISCO trail.Direct stenting of coronary arteries[J]. Eur Heart J, 2002:23:633-40
2 Mudra H, di Mario C, de Jaegere P, Figulla H, Macaya C, Zahn R, et al. Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study)[J]. Circulation, 2001;104:1343-9
3 Wohrle J, AI-Khayer E, Grotzinger U, et al. Comparison of the heparin coated vs.the uncoated Jostent:no influence on restenosis or clinical outcome[J]. Eur Heart J, 2001;22:1808-16
4 Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary, revascularization[J]. A Engl J Med, 2002;346:1773-80
5 Serruys PW, DegertekinM, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial[J]. Circulation, 2002;106(7):798-803
6 Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial:instent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation[J]. Circulation,2003;107(4):559-64
7 Park SJ, Shim WH, Ho DS, et al. The clinical effectiveness of paclitaxel-coated coronary stents for the reduction of restenosis in the ASPECT trial[J]. Circulation, 2001;104(suppl II):II-464
8 Gershlick AH, De Scheerder I, Chevalier B, et al. Local drug delivery to inhibit coronary artery restenosis:data from the ELUTES (Evaluation of Paclitaxel Eluting Stent) clinical trial[J]. Circulation, 2001;104(suppl Il):II-416
9 Grube E, Silber SM, Hauptmann KE.TAXUS I:prospective, randomized, double-blind comparison of NIRx stents coated with paclitaxel in carrier de novo coronary lesions compared with uncoated controls[J]. Circulation, 2001;104(suppl II):II-463
10 Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I:six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions[J]. Circulation,2003;107(1):38-42
11 Lovdahl C, Thyberg J, Hultgardh-Nilsson A.The synthetic metalloproteinase inhibitor batimastat suppresses injury-induced phosphorylation of MAP kinase ERK1 ERK2 and phenotypic modification of arterial smooth muscle cells in vitro[J]. J Vasc Res, 2000;37:345-54
12 Grube E, Hauptmann K, Colombo A, et al. SCORE trial interim safety results:despite efficacy, late stent thrombosis with the QuaDDS-QP2 stent[J]. J Am Coll Cardiol, 2002;39(supplA):38A
13 Honda Y, Grube E, de la Fuente LM, et al. Novel drug delivery stent:intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system[J]. Circulation, 2001;104:380-3
14 Gruntzig A.Transluminal dilatation of coronary artery stenosis[J]. Lancet, 1978;1:263 |
